NEW YORK (GenomeWeb News) – Intradigm has licensed siRNA technology from the University of Massachusetts Medical School that will help in its RNAi-based therapeutics programs, the company said today.
The UMass intellectual property covers “certain efficacy-enhancing structural elements” of siRNA, as well as parameters for structural modifications that will help the company “significantly improve the potency and efficacy of RNAi therapeutics,” Intradigm said.
The Palo Alto, Calif.-based company said its RNAi NPX delivery technology carries active siRNA molecules that can help improve circulation half life and selective distribution to targeted tissue.
The company’s multi-targeted therapeutics can silence several mRNAs representing parallel or synergistic elements of the same disease pathway, Intradigm said.
Financial terms of the agreement were not released.